Insulin-like growth factor I is an independent coregulatory modulator of natural killer (NK) cell activity

Endocrinology

Volumn 137, Issue 12, 1996, Pages 5332-5336

  Auernhammer, C J ^a   Feldmeier, H ^a   Nass, R ^a   Pachmann, K ^a   Strasburger, C J ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; CD16 ANTIGEN; EUROPIUM; HUMAN GROWTH HORMONE; MONOCLONAL ANTIBODY CD3; SOMATOMEDIN C;

ADULT; ARTICLE; CELL STRAIN K 562; CLINICAL ARTICLE; CONTROLLED STUDY; EFFECTOR CELL; FEMALE; FLOW CYTOMETRY; GROWTH HORMONE DEFICIENCY; HUMAN; HUMAN CELL; IMMUNOMODULATION; LEUKEMIA; LYMPHOCYTE SUBPOPULATION; MALE; NATURAL KILLER CELL; ONSET AGE; PRIORITY JOURNAL;

EID: 0030457773     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/endo.137.12.8940354     Document Type: Article

References (26)

1. Gala RR 1991 Prolactin and growth hormone in the regulation of the immune system. Proc Soc Exp Biol Med 198:513-527
2. Kelley KW, Arkins S, Li YM 1992 Growth hormone, prolactin, and insulin-like growth factors: new jobs for old players. Brain Behav Immun 6:317-326
3. Hooghe R, Delhase M, Vergani P, Malur A, Hooghe-Peters EL 1993 Growth hormone and prolactin are paracrine growth and differentiation factors in the haemopoietic system. Imnumol Today 14:212-214
4. Auernhammer CJ, Strasburger CJ 1995 Effects of growth hormone and insulin-like growth factor I on the immune system. Eur J Endocrinol 133:635-645
5. Badolato R, Bond HM, Valerio G, Petrella A, Morrone G, Waters MJ, Venuta S, Tenore A 1994 Differential expression of surface membrane growth hormone receptor on human peripheral blood lymphocytes detected by dual fluorochrome flow cytometry. J Clin Endocrinol Metab 79:984-990
6. Kooijman R, Willems M, De Haas CJC, Rijkers GT, Schuurmans AL, Van Buul-Offers SC, Heijnen CJ, Zegers BJ 1992 Expression of type 1 insulin-like growth factor receptors on human peripheral blood mononuclear cells. Endocrinology 131:2244-2250
7. Igarashi N, Takakuwa S 1994 Flow cytometric analysis of insulin-like growth factor-I (IGF-I) receptors on human blood cells. Clin Pediatr Endocrinol 3(Suppl 5):168-170
8. Perussia B 1991 Lymphokine-activated killer cells, natural killer cells and cytokines. Curr Opin Immunol 3:49-55
9. Lanier LL, Phillips JH 1992 Natural killer cells. Curr Opin Immunol 4:38-42
10. Moretta L, Ciccone E, Mingari MC, Biassoni R, Moretta A 1994 Human natural killer cells: origin, clonality, specificity, and receptors. Adv Immunol 55:341-380
11. Kiess W, Doerr H, Eisl E, Butenandt O, Belohradsky BH 1986 Lymphocyte subsets and natural-killer activity in growth hormone deficiency [letter]. N Engl J Mod 314:321
12. Kiess W, Malozowski S, Gelato M, Butenand O, Doerr H, Crisp B, Eisl E, Maluish A, Belohradsky BH 1988 Lymphocyte subset distribution and natural killer activity in growth hormone deficiency before and during short-term treatment with growth hormone releasing hormone. Clin Immunol Immunopathol 48:85-94
13. Bozzola M, Cisternino M, Larizza D, Maghnie M, Moretta A, Valtorta A, Schimpff RM, Severi F 1989 Correspondence: to the editor. Metabolism 38:193
14. Crist DM, Peake GT, Mackinnon LT, Sibbitt Jr WL, Kraner JC 1987 Exogenous growth hormone treatment alters body composition and increases natural killer cell activity in women with impaired endogenous growth hormone secretion. Metabolism 36:1115-1117
15. Watanabe S, Mizuno S, Tsunematsu Y, Komiyama A, Yamanaka C, Kubota M 1994 Leukemia in GH deficient children. Clin Pediatr Endocrinol 3(Suppl 5):53-60
16. Boyum A 1976 Isolation of lymphocytes, granulocytes and macrophages. Scand J Immunol 5(Suppl 5):9-15
17. Blomberg K, Granberg C, Hemmilä I, Lövgren T 1986 Europium-labelled target cells in an assay of natural killer cell activity. I. A novel non-radioactive method based on time-resolved fluorescence. J Immunol Methods 86:225-229
18. Blomberg K, Granberg C, Hemmilä I, Lövgren T 1986 Europium-labelled target cells in an assay of natural killer cell activitv. II. A novel non-radioactive method based on time-resolved fluorescence. Significance and specifity of the method. J Immunol Methods 92:117-123
19. Maley DT, Simon P 1990 Cytotoxicity assay using cryopreserved target cells pro-labeled with the fluorescent marker europium. J Immunol Methods 134:61-70
20. Blum WF, Gallaher B, Ranke MB, An IGFBP-blocked IGF-I RIA that measures what it pretends to measure: IGF-I. Program of the 74th Annual Meeting of The Endocrine Sociey, San Antonio, TX, 1992, p 968 (Abstract)
21. Strasburger CJ, Dressendörfer RA, Lee PDK 1994 Non-isotopic, two-site immunoassay for IGFBP-3. Growth Regul 4(Suppl 1):138 (Abstract)
22. Cianfarani S, Boemi S, Spagnoli A, Cappa M, Argiro G, Vaccaro F, Manca Bitti ML, Boscherini B 1995 Is IGF binding protein-3 assessment helpful for the diagnosis of GH deficiency? Clin Endocrinol (Oxf) 43:43-47
23. de Herder WW, van der Lely AJ, Janssen JAMJL, Uitterlinden P, Hofland LJ, Lamberts SWJ 1995 IGFBP-3 is a poor parameter for assessment of clinical activity in acromegaly. Clin Endocrinol (Oxf) 43:501-505
24. Frystyk J, Skjaerbaek C, Dinessen B, Orskov H 1994 Free insulin-like growth factors (IGF-I and IGF-II) in human serum. FEBS Lett 348:185-191
25. Weigent DA, Blalock JE 1991 The production of growth hormone by subpopulations of rat mononuclear leukocytes. Cell Immunol 135:55-65
26. Pross HF, Lotzova E 1993 Role of natural killer cells in cancer. Nat Immun 12:279-292